Malaysia plant boosts Biocon prospects in US and other key markets

Topics Biocon | US FDA | insulin

Even as the benchmark indices declined 6.4 per cent over two sessions, the Biocon stock jumped 8 per cent during this period. The gains came after the company received a go-ahead (EIR) from the US drug regulator, following an inspection of its insulin manufacturing facility in Malaysia. EIR refers to establishment inspection report, granted by the US FDA upon closure of its inspection. This paves the way for approval (to launch) and commercialisation of insulin (Glarg­ine) in the US. The company, along with its partner, had already won a patent ligation for insulin Glargine in the US.....

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel
Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.